GlassScriptPhysician profile
Henry R Tseng
NPI 1295733855
$10,068.65
in general payments reported to CMS, 2019-2025
22 companies · $936 in 2025
The $936 reported for 2025 was more than what 79% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $162 · 2021: $341 · 2022: $434 · 2023: $1,010 · 2024: $6,667 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,050 · Food and Beverage: $3,556 · Travel and Lodging: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,050.00 |
| Food and Beverage | $3,555.65 |
| Travel and Lodging | $1,007.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,225.44 | 2024-2025 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $793.19 | 2021-2025 | Nuzyra |
| Smith+Nephew, INC. | $649.46 | 2019-2025 | Oasis, Stravix, Grafix Pl |
| Horizon Therapeutics Plc | $437.65 | 2022-2023 | Krystexxa |
| Cardiovascular Systems INC. | $368.71 | 2019-2021 | |
| Stryker Corporation | $342.02 | 2024-2025 | Prophecy, Augment Injectable |
| Inari Medical, INC. | $234.98 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bioventus LLC | $178.23 | 2019-2022 | |
| Abbott Laboratories | $149.78 | 2023 | Eterna |
| Abbvie INC. | $149.27 | 2021-2024 | Dalvance |
| Depuy Synthes Sales INC. | $109.57 | 2023 | |
| Melinta Therapeutics, LLC | $95.94 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $89.92 | 2025 | Purified Cortrophin Gel |
| Angiodynamics, INC. | $62.69 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $51.03 | 2023 | Seglentis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sebela Pharmaceuticals INC. | $32.64 | 2022 | |
| Venclose INC. | $26.81 | 2020 | |
| Boston Scientific Corporation | $17.19 | 2021 | |
| Hartmann USA, INC. | $16.70 | 2023 | Zetuvit Plus |
| Solventum Corporation | $13.50 | 2025 | Activ.A.C. |
| Biotissue Holdings INC. | $12.12 | 2021 | |
| Nabriva Therapeutics, Plc | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.